Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer Context Therapeutics (Nasdaq: CNTX) announced that the FDA granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for treatment of platinum-resistant ovarian cancer (PROC).CTIM-76 is in a Phase 1 trial evaluating safety, tolerability, pharmacokinetics and anti-tumor activity in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers. The company expects interim Phase 1a data in June 2026.

#CNTX Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Reports Full Year 2025 Operating and Financial Results Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA,

#CNTX Context Therapeutics Reports Full Year 2025 Operating and Financial Results

www.stocktitan.net/news/CNTX/context-therap...

Context will show preclinical CT-202 tumor data at April cancer meeting AACR poster will feature preclinical CT-202 data in the Clinical Research session on April 21 in San Diego; abstract 5392 posts at session start.

#CNTX Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

www.stocktitan.net/news/CNTX/context-therap...

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Dec 4th - #YB #NA #MAMO #LASE #DRMA #CNTX #SYBX #SVCO #PLRX #NDRA #KITT #EKSO #CBIO #BBNX #ZKH #NOAH #GCO #ECVT #BBW - More: crystalequityresearch.com/leading-indi... - #smallcap

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company’s CT-95 and

#CNTX Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results Context Therapeutics (Nasdaq: CNTX) reported third-quarter 2025 results and a clinical update on its T cell engager pipeline. As of September 30, 2025, cash and cash equivalents were $76.9 million and the company expects runway into 2027. The company reported a Q3 2025 net loss of $9.7 million versus $17.5 million in Q3 2024 and R&D expense of $8.7 million versus $16.8 million a year earlier, driven largely by lower CT-202 and CT-95 spend.Clinical highlights: CTIM-76 (CLDN6 x CD3) has enrolled 12 patients (cutoff Oct 30, 2025), shows preliminary RECIST responses beginning in Cohort 3, no CRS > Grade 1, no DLT, and MTD not reached; updated Phase 1a/Phase 1b dose selection expected Q2 2026. CT-95 (MSLN x CD3) has enrolled 6 patients, is in Cohort 3 with target exposure projected at Cohort 4, no DLT, and no CRS > Grade 2; initial Phase 1a data expected mid-2026. CT-202 remains preclinical with planned filings toward a first-in-human trial in Q2 2026.

#CNTX Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting Context Therapeutics (NASDAQ:CNTX) will present two poster presentations at the Society for Immunotherapy of Cancer 40th Annual Meeting, November 7–9, 2025, in National Harbor, MD.One poster is a Trial in Progress for the Phase 1, first‑in‑human study of CT-95 (mesothelin x CD3 TCE) in advanced solid tumors (Abstract #586), scheduled Saturday, November 8, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls. The second poster covers preclinical efficacy, safety, and PK data for CT-202 (Nectin-4 x CD3 TCE) (Abstract #963), scheduled Friday, November 7, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls.Abstracts are available via the SITC 40th Annual Meeting website.

#CNTX Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 Novel T cell engager targeting 3 cancer types enters third dosing cohort. Phase 1 trial expanding to 7 US sites, with initial efficacy data expected H1 2026. See trial details.

#CNTX Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer Former Adaptimmune SVP who led groundbreaking solid tumor therapy approval joins Context to advance T-cell bispecific portfolio. See strategic impact.

#CNTX Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results Context Therapeutics (CNTX) reported Q1 2025 financial results and business updates. The company has $89.4 million in cash, expected to fund operations into 2027. Two product candidates are in Phase 1 clinical trials: CTIM-76 (Claudin 6 x CD3 bispecific antibody) and CT-95 (mesothelin x CD3 bispecific antibody). Initial clinical data is expected in H1 2026 for CTIM-76 and mid-2026 for CT-95. The company reported a net loss of $4.6 million for Q1 2025, compared to $3.7 million in Q1 2024. R&D expenses increased to $3.5 million from $2.0 million year-over-year. Context plans to file an IND for CT-202, a Nectin-4 x CD3 bispecific antibody, in mid-2026.

#CNTX Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/CNTX/context-therap...

Former Jazz Pharmaceuticals R&D Head Dr. Karen Smith Steps in as Context Therapeutics Interim CMO: What This Means for Clinical Pipeline Distinguished biotech veteran Dr. Karen Smith, with 20+ years experience at Jazz Pharma, Allergan, and AstraZeneca, to guide Context's T-cell therapy pipeline. Learn more.

#CNTX Context Therapeutics Announces Chief Medical Officer Transition

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting Context Therapeutics presented preclinical and translational data for their cancer treatment candidate CT-95 at the 2025 AACR Annual Meeting in Chicago. CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody designed to treat solid tumors. Key findings from the preclinical studies show that CT-95: Selectively binds to mesothelin-expressing cells Targets a unique membrane-proximal region of mesothelin Avoids impact of shed mesothelin sink Demonstrates high activity and good tolerance in various models Activates T cells without broad cytokine release The company has already begun Phase 1 clinical trials and expects to share initial clinical data by mid-2026. The treatment targets mesothelin expressing cancers, including pancreatic, ovarian, and mesothelioma, addressing a significant unmet medical need.

#CNTX Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

www.stocktitan.net/news/CNTX/context-therap...

Breakthrough Cancer Treatment Launches Trial: Targets 30% of All Cancer Types Novel T cell therapy CT-95 begins clinical testing for advanced solid tumors. Targets mesothelin protein found in multiple cancers. See trial details inside.

#CNTX Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

www.stocktitan.net/news/CNTX/context-therap...

Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 New preclinical data reveals optimal first-in-human dosing strategy for CT-95 bispecific antibody, advancing Context's innovative cancer treatment pipeline. Full analysis inside.

#CNTX Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Reports Full Year 2024 Operating and Financial Results Context Therapeutics (CNTX) reported its full year 2024 financial results and business highlights. The company ended 2024 with $94.4 million in cash, expected to fund operations into 2027. Key developments include the first patient dosed with CTIM-76 in January 2025 for CLDN6-positive cancers, acquisition of CT-95, and in-licensing of CT-202.Financial results show R&D expenses increased to $22.7 million in 2024 from $17.8 million in 2023, primarily due to $14.75 million in research charges related to CT-95 acquisition and CT-202 licensing. The company reported a net loss of $26.7 million for 2024, compared to $24.0 million in 2023.Upcoming milestones include first patient dosing for CT-95 in Q2 2025, initial CTIM-76 clinical data in H1 2026, and CT-95 trial data in mid-2026.

#CNTX Context Therapeutics Reports Full Year 2024 Operating and Financial Results

www.stocktitan.net/news/CNTX/context-therap...

Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 First patient dosed in trial evaluating CTIM-76, targeting CLDN6-positive gynecologic and testicular cancers. Study to enroll 70 patients with data expected in H1 2026.

#CNTX Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

www.stocktitan.net/news/CNTX/context-therap...

Just In: ( NASDAQ: #CNTX ) Context Therapeutics to Participate in Upcoming Investor Conferences in November

#StockMarket #News